Croda Enters Contract With Pfizer for Innovative Delivery System for COVID-19 Vaccine
Croda International Plc, the speciality chemical company that uses smart science to create high-performance ingredients and technologies that improve lives, recently announced it has entered into an agreement with Pfizer Inc. to supply novel excipients used in the manufacture of a COVID-19 vaccine candidate. The contract with Pfizer runs for 5 years and awards Croda an initial supply contract for four component excipients used in the production of the vaccine candidate for the first 3 years of the contract. Demand remains subject to relevant approvals.
Croda’s recently acquired subsidiary, Avanti Polar Lipids, Inc. (Avanti), specializes in the development and production of high-purity lipids, to produce research and clinical trial quantities of excipients in order to stabilize formulations and enable delivery into the body by parenteral mechanism (injection) for drug and vaccine applications. Croda’s existing health care business has a 20-year track record in developing IP-rich, innovative technologies for drug delivery systems for the pharmaceutical industry and has been working with Avanti, prior to and since its acquisition by Croda, to refine the complex processes involved in achieving the volumes of high-purity excipients required by its pharmaceutical customers. Croda has reprioritized investment, resources, and other projects across the Group over the past few months to focus on the delivery of this project.
Commenting on the new contract, Steve Foots, Chief Executive Officer, said “I’m very proud of Croda’s involvement in the battle to fight the most significant pandemic that we have seen in a generation. The application of our innovative capabilities is testament to the strong progress we have made to create industry-leading drug delivery systems, focused on developing speciality excipients and adjuvants to improve the effectiveness and stability of complex drug actives and vaccines. It is another example of why our Purpose – Smart Science to Improve Lives – sits at the heart of our strategy and will continue to drive our priorities and ambitions in the years ahead.”
Part of the Life Sciences business, Croda Health Care is a long-established supplier of choice to the pharmaceutical, vaccine adjuvant, nutritional, consumer and animal health markets. With a wide and constantly growing range of products, including high performance excipients, vaccine adjuvants and solubilisers, the Health Care portfolio is unsurpassed in excellence. This offering, along with our in-house formulation expertise, helps Croda Health Care meet the most stringent customer demands and future health and wellbeing needs.
Croda International Plc profile
Established in 1925, Croda is the name behind sustainable, high performance ingredients and technologies in some of the world’s most successful brands: creating, making, and selling speciality chemicals that are relied on by industries and consumers everywhere. For more information, visit www.croda.com.
Croda is a FTSE 100 company with over 4,500 passionate and innovative employees, working across manufacturing sites and offices around the world with a shared Purpose to use Smart Science to Improve Lives™. As part of this Purpose, and with around two thirds of its organic raw materials already from bio-based sources, Croda has committed to be the most sustainable supplier of innovative ingredients, becoming Climate, Land and People Positive by 2030.
Smart Science to Improve Lives™
Croda Health Care profile
Total Page Views: 200